Pharmacotherapy in sickle cell disease—state of the art and future prospects. (avab uue akna)

Hankins J, Aygun B.

Allikas‎: Br J Haematol 2009;145(3):296-308.

Indekseeritud‎: PubMed 19222472

DOI‎: 10.1111/j.1365-2141.2009.07602.x

https://www.ncbi.nlm.nih.gov/pubmed/19222472 (avab uue akna)

Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. (avab uue akna)

Hankins JS, Ware RE, Rogers ZR, Wynn LW, Lane PA, Scott JP, Wang WC.

Allikas‎: Blood 2005;106(7):2269-75.

Indekseeritud‎: PubMed 16172253

DOI‎: 10.1182/Blood-2004-12-4973

https://www.ncbi.nlm.nih.gov/pubmed/16172253 (avab uue akna)

Hydroxyurea dose escalation for sickle cell anemia in sub-Saharan Africa. (avab uue akna)

John CC, Opoka RO, Latham TS, Hume HA, Nabaggala C, Kasirye P, Ndugwa CM, Lane A, Ware RE

Allikas‎: N Engl J Med 2020;382(26):2524-33.

Indekseeritud‎: PubMed 32579813

DOI‎: 10.1056/NEJMoa2000146

https://www.ncbi.nlm.nih.gov/pubmed/32579813 (avab uue akna)

The effect of hydroxcarbamide therapy on survival of children with sickle cell disease. (avab uue akna)

Lobo CL, Pinto JF, Nascimento EM, Moura PG, Cardoso GP, Hankins JS.

Allikas‎: Br J Haematol 2013;161(6):852-60.

Indekseeritud‎: PubMed 23590693

DOI‎: 10.1111/bjh.12323

https://www.ncbi.nlm.nih.gov/pubmed/23590693 (avab uue akna)

Evidence review of hydroxyurea for the prevention of sickle cell complications in low-income countries. (avab uue akna)

Mulaku M, Opiyo N, Karumbi J, Kitonyi G, Thoithi G, English M.

Allikas‎: Arch Dis Child 2013;98(11):908-14.

Indekseeritud‎: PubMed 23995076

DOI‎: 10.1136/archdischild-2012-302387

https://www.ncbi.nlm.nih.gov/pubmed/23995076 (avab uue akna)

Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children. (avab uue akna)

Strouse JJ, Lanzkron S, Beach MC, Haywood C, Park H, Witkop C, Wilson RF, Bass EB, Segal JB.

Allikas‎: Pediatrics 2008;122(6):1332-42.

Indekseeritud‎: PubMed 19047254

DOI‎: 10.1542/peds.2008-0441

https://www.ncbi.nlm.nih.gov/pubmed/19047254 (avab uue akna)

Impact of hydroxyurea on clinical events in the BABY HUG trial. (avab uue akna)

Thornburg CD, Files BA, Luo Z, Miller ST, Kalpatthi R, Iyer R, Seaman P, Lebensburger J, Alvarez O, Thompson B, Ware RE, Wang WC; BABY HUG Investigators.

Allikas‎: Blood 2012;120(22):4304-10.

Indekseeritud‎: PubMed 22915643

DOI‎: 10.1182/blood-2012-03-419879

https://www.ncbi.nlm.nih.gov/pubmed/22915643 (avab uue akna)

Hydroxyurea for children with sickle cell anemia in sub-Saharan Africa. (avab uue akna)

Tshilolo L, Tomlinson G, Williams TN, Santos B, Olupot-Olupot P, Lane A, Aygun B, Stuber SE, Latham TS, McGann PT, Ware RE; REACH Investigators

Allikas‎: N Engl J Med 2019;380(2):121-31.

Indekseeritud‎: PubMed 30501550

DOI‎: 10.1056/NEJMoa1813598

https://www.ncbi.nlm.nih.gov/pubmed/30501550 (avab uue akna)

Effect of hydroxyurea on growth in children with sickle cell anemia: results of the HUG-KIDS Study. (avab uue akna)

Wang WC, Helms RW, Lynn HS, Redding-Lallinger R, Gee BE, Ohene-Frempong K, Smith-Whitley K, Waclawiw MA, Vichinsky EP, Styles LA, Ware RE, Kinney TR.

Allikas‎: J Pediatr 2002;140(2):225-9.

Indekseeritud‎: PubMed 11865275

DOI‎: 10.1067/mpd.2002.121383

https://www.ncbi.nlm.nih.gov/pubmed/11865275 (avab uue akna)

Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. (avab uue akna)

Wang WC, Oyeku SO, Luo Z, Boulet SL, Miller ST, Casella JF, Fish B, Thompson BW, Grosse SD; BABY HUG Investigators.

Allikas‎: Pediatrics 2013;132(4):677-83.

Indekseeritud‎: PubMed 23999955

DOI‎: 10.1542/peds.2013-0333

https://www.ncbi.nlm.nih.gov/pubmed/23999955 (avab uue akna)

Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). (avab uue akna)

Wang WC, Ware RE, Miller ST, Iyer RV, Casella JF, Minniti CP, Rana S, Thornburg CD, Rogers ZR, Kalpatthi RV, Barredo JC, Brown RC, Sarnaik SA, Howard TH, Wynn LW, Kutlar A, Armstrong FD, Files BA, Goldsmith JC, Waclawiw MA, Huang X, Thompson BW; for the BABY HUG investigators.

Allikas‎: Lancet 2011;377(9778):1663-72.

Indekseeritud‎: PubMed 21571150

DOI‎: 10.1016/S0140-6736(11)60355-3

https://www.ncbi.nlm.nih.gov/pubmed/21571150 (avab uue akna)

Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. (avab uue akna)

Ware RE, Davis BR, Schultz WH, Brown RC, Aygun B, Sarnaik S, Odame I, Fuh B, George A, Owen W, Luchtman-Jones L, Rogers ZR, Hilliard L, Gauger C, Piccone C, Lee MT, Kwiatkowski JL, Jackson S, Miller ST, Roberts C, Heeney MM, Kalfa TA, Nelson S, Imran H, Nottage K, Alvarez O, Rhodes M, Thompson AA, Rothman JA, Helton KJ, Roberts D, Coleman J, Bonner MJ, Kutlar A, Patel N, Wood J, Piller L, Wei P, Luden J, Mortier NA, Stuber SE, Luban NL, Cohen AR, Pressel S, Adams RJ.

Allikas‎: Lancet 2016;387(10019):661-70.

Indekseeritud‎: PubMed 26670617

https://www.ncbi.nlm.nih.gov/pubmed/26670617 (avab uue akna)

How I use hydroxyurea to treat young patients with sickle cell anemia. (avab uue akna)

Ware RE.

Allikas‎: Blood 2010;115(26):5300-11.

Indekseeritud‎: PubMed 20223921

DOI‎: 10.1182/blood-2009-04-146852

https://www.ncbi.nlm.nih.gov/pubmed/20223921 (avab uue akna)

Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. (avab uue akna)

Zimmerman SA, Schultz WH, Davis JS, Pickens CV, Mortier NA, Howard TA, Ware RE.

Allikas‎: Blood 2004;103(6):2039-45.

Indekseeritud‎: PubMed 14630791

DOI‎: 10.1182/blood-2003-07-2475

https://www.ncbi.nlm.nih.gov/pubmed/14630791 (avab uue akna)

Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease. (avab uue akna)

Hirst C, Owusu-Ofori S.

Allikas‎: Cochrane Database Syst Rev 2012;(9):CD003427.

Indekseeritud‎: PubMed 22972063

DOI‎: 10.1002/14651858.CD003427.pub2

https://www.ncbi.nlm.nih.gov/pubmed/22972063 (avab uue akna)

Sickle cell disease. (avab uue akna)

Meremikwu MM, Okomo U.

Allikas‎: BMJ Clin Evid 2011;02:2402.

Indekseeritud‎: PubMed 21718552

https://www.ncbi.nlm.nih.gov/pubmed/21718552 (avab uue akna)

A phase 3 trial of l-glutamine in sickle cell disease. (avab uue akna)

Niihara Y, Miller ST, Kanter J, Lanzkron S, Smith WR, Hsu LL, Gordeuk VR, Viswanathan K, Sarnaik S, Osunkwo I, Guillaume E, Sadanandan S, Sieger L, Lasky JL, Panosyan EH, Blake OA, New TN, Bellevue R, Tran LT, Razon RL, Stark CW, Neumayr LD, Vichinsky EP

Allikas‎: N Engl J Med 2018;379(3):226-35.

Indekseeritud‎: PubMed 30021096

DOI‎: 10.1056/NEJMoa1715971

https://www.ncbi.nlm.nih.gov/pubmed/30021096 (avab uue akna)

Hydroxyurea treatment is associated with lower malaria incidence in children with sickle cell anemia in sub-Saharan Africa. (avab uue akna)

Olupot-Olupot P, Tomlinson G, Williams TN, Tshilolo L, Santos B, Smart LR, McElhinney K, Howard TA, Aygun B, Stuber SE, Lane A, Latham TS, Ware RE

Allikas‎: Blood. 2023 23;141(12):1402-10.

Indekseeritud‎: PubMed 36375125

DOI‎: 10.1182/blood.2022017051

https://pubmed.ncbi.nlm.nih.gov/36375125/ (avab uue akna)

Malaria chemoprophylaxis in sickle cell disease. (avab uue akna)

Oniyangi O, Omari AA.

Allikas‎: Cochrane Database Syst Rev 2006;(4):CD003489.

Indekseeritud‎: PubMed 17054173

DOI‎: 10.1002/14651858.CD003489.pub2

https://www.ncbi.nlm.nih.gov/pubmed/17054173 (avab uue akna)